Fig. 3From: Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trialsPercent change from baseline in SDAI in patients with early RA from a PREMIER and b OPTIMA, or established RA from c DE019 and d ARMADA at week 24/26. P value for difference between response rates for patients treated with ADA+MTX and PBO+MTX. ADA, adalimumab; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis; SDAI, Simplified Disease Activity IndexBack to article page